Romark’s investigational Covid-19 drug lowers disease progression in trial
15th April 2021 (Last Updated April 15th, 2021 17:33)
Romark has reported that initial results from a Phase III clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets, 300mg) demonstrated to reduce disease progression in mild or moderate Covid-19 patients.
The trial enrolled 1,092 subjects aged 12 years and above with respiratory symptoms consistent with Covid-19. Credit: Ewa Urban from Pixabay.
Share Article
Romark has reported that initial results from a Phase III clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets, 300mg) demonstrated to reduce disease progression in mild or moderate Covid-19 patients.